Drug compliance in patients with systemic scleroderma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10124574" target="_blank" >RIV/00179906:_____/12:10124574 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10124574 RIV/00216208:11160/12:10124574

Výsledek na webu

<a href="http://link.springer.com/content/pdf/10.1007/s10067-012-2050-0" target="_blank" >http://link.springer.com/content/pdf/10.1007/s10067-012-2050-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10067-012-2050-0" target="_blank" >10.1007/s10067-012-2050-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Drug compliance in patients with systemic scleroderma

Popis výsledku v původním jazyce

Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (}=80 %). No relationships between various demographic and cli

Název v anglickém jazyce

Drug compliance in patients with systemic scleroderma

Popis výsledku anglicky

Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (}=80 %). No relationships between various demographic and cli

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Rheumatology

ISSN

0770-3198

e-ISSN

—

Svazek periodika

31

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

1577-1583

Kód UT WoS článku

000310379500007

EID výsledku v databázi Scopus

—